Advertisement

Porcine Malignant Hyperthermia

  • Gerald A. Gronert
Conference paper

Abstract

Porcine malignant hyperthermia (MH) differs from human MH in that it is a homozygotic expression of a single point mutation in all muscular species. This mutation probably occurred about 100–150 years ago. Pigs were bred then, as now, with the idea that selection of the most muscular offspring, followed by line breeding, would produce the most valuable marketable animal: lean, muscular, with little fat and rapid development of the muscular build. Unfortunately, not all characteristics were desirable. Although rapid development of lean body mass represented a true hybrid vigor, a rather marked disadvantage was an obvious overt sensitivity to stress. Certain stress, such as fright, shipping, coitus, and fighting, led to a process identical to MH episodes generally produced by triggering anesthetics: rigidity, tachycardia, tachypnea, acidosis, high fever, and death. This end result could occur in as few as 10 min, with a body temperature greater than 43°C.

Keywords

Ryanodine Receptor Malignant Hyperthermia Malignant Hyperthermia Suxamethonium Chloride Dantrolene Sodium 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Fujii J, Otsu K, Zorzato F, et al (1991) Identification of a mutation in porcine ryanodine receptor associated with malignant hyperthermia. Science 253: 448–451PubMedCrossRefGoogle Scholar
  2. 2.
    Herter M, Wilsdorf G (1914) Die Bedeutung des Schweines für die Fleischversorgung. Arbeiten der Deutscher Landwirtschaft-Gesellschaft, Berlin, Heft 270Google Scholar
  3. 3.
    Ludvigsen J (1953) Muscular degeneration in hogs (preliminary report). In: Proceedings, 15th international veterinary congress, Stockholm, 1953, vol VIGoogle Scholar
  4. 4.
    Briskey EJ (1964) Etiological status and associated studies of pale, soft, exudative porcine musculature. Adv Food Res 13: 89–178PubMedCrossRefGoogle Scholar
  5. 5.
    Topel DG, Bicknell EJ, Preston KS, et al (1968) Porcine stress syndrome. Mod Vet Pract 49: 40–41;Google Scholar
  6. 6.
    Hall LW, Woolf N, Bradley JWP, Jolly DW (1966) Unusual reaction to suxamethonium chloride. Br Med J 2: 1305PubMedCrossRefGoogle Scholar
  7. 7.
    Sybesma W, Eikelenboom G (1969) Malignant hyperthermia syndrome in pigs. Neth J Vet Sci 2: 155–160Google Scholar
  8. 8.
    Berman MC, Harrison GG, Bull AB, Kench JE (1970) Changes underlying halothaneinduced malignant hyperpyrexia in Landrace pigs. Nature 225: 653–655PubMedCrossRefGoogle Scholar
  9. 9.
    Nelson TE, Jones EW, Henrickson RL, Falk SN, et al (1974) Porcine malignant hyperthermia: observations on the occurrence of pale, soft, exudative musculature among susceptible pigs. Am J Vet Res 35: 347–350PubMedGoogle Scholar
  10. 10.
    Gronert GA, Heffron JJA, Milde JH, Theye RA (1977) Porcine malignant hyperthermia: role of skeletal muscle in increased oxygen consumption. Can Anaesth Soc J 24: 103–109PubMedCrossRefGoogle Scholar
  11. 11.
    Lucke JN, Hall GM, Lister D (1979) Malignant hyperthermia in the pig and the role of stress. Ann NY Acad Sci 317: 326–337PubMedGoogle Scholar
  12. 12.
    Harrison GG (1975) Control of the malignant hyperpyrexic syndrome in MHS swine by dantrolene sodium. Br J Anaesth 47: 62–65PubMedCrossRefGoogle Scholar
  13. 13.
    Mickelson JR, Knudson CM, Kennedy CFH, et al (1992) Structural and functional correlates of a mutation in the malignant hyperthermia-susceptible pig ryanodine receptor. FEBS Lett 301: 49–52PubMedCrossRefGoogle Scholar
  14. 14.
    Gallant EM (1992) Lentz LR. Excitation-contraction coupling in pigs heterozygous for malignant hyperthermia. Am J Physiol 262: C422–C426PubMedGoogle Scholar
  15. 15.
    Gronert GA, Milde JH, Theye RA (1977) Role of sympathetic activity in porcine malignant hyperthermia. Anesthesiology 47: 411–415PubMedCrossRefGoogle Scholar
  16. 16.
    Gallant EM, Foldes FF, Rempel WE, Gronert GA (1985) Verapamil is not a therapeutic adjunct to dantrolene in porcine malignant hyperthermia. Anesth Analg 64: 601–606PubMedCrossRefGoogle Scholar
  17. 17.
    Gallant EM, Fletcher TF, Goettl VM, Rempel WE (1986) Porcine malignant hyperthermia: cell injury enhances halothane sensitivity of biopsies. Muscle Nerve 9: 174–194PubMedCrossRefGoogle Scholar
  18. 18.
    Gallant EM, Godt RE, Gronert GA (1980) Mechanical properties of normal and malignant hyperthermia susceptible porcine muscle: effects of halothane and other drugs. J Pharmacol Exp Ther 213: 91–96PubMedGoogle Scholar
  19. 19.
    Gronert GA, Ahern CP, Milde JH, White RD (1986) Effect of CO, calcium, digoxin, and potassium on cardiac and skeletal muscle metabolism in malignant hyperthermia susceptible swine. Anesthesiology 64: 24–28PubMedCrossRefGoogle Scholar
  20. 20.
    Lopez JR, Allen PD, Alamo L, et al (1988) Myoplasmic free [Caz+] during a malignant hyperthermia episode in swine. Muscle Nerve 11: 82–88PubMedCrossRefGoogle Scholar
  21. 21.
    Lamb GD (1993) Caz+ inactivation, Mgt+ inhibition and malignant hyperthermia. J Muscle Res Cell Motil 14: 554–556PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Tokyo 1996

Authors and Affiliations

  • Gerald A. Gronert
    • 1
  1. 1.Department of AnesthesiaUniversity of CaliforniaDavisUSA

Personalised recommendations